Fertility Germline Testing denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for fertility germline testing are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Fertility Germline Testing
## Why Cigna Denied Fertility-Related Germline Testing as Duplicate
Cigna's duplicate-therapy denial for germline genetic testing typically means their records show that a similar or overlapping genetic test was already performed and resulted in a covered claim — or that another test currently under authorization covers the same genetic variants being requested.
This denial is frequently based on billing-code overlap rather than true clinical duplication, and is often overturnable when the ordering provider documents why the new test is clinically distinct or additive.
## Why It Happens and Why It Is Appealable
Germline testing in the context of fertility or reproductive planning can encompass multiple distinct clinical purposes: carrier screening for heritable conditions, hereditary cancer predisposition testing that informs egg or embryo selection, and preimplantation genetic testing (PGT) panels. Each of these addresses a different clinical question, and prior testing for one purpose does not render subsequent testing for a different purpose duplicative.
## Federal Appeal Rights
- ERISA §503 (employer-sponsored plans): full-and-fair internal review by a qualified clinical reviewer.
- ACA §2719 (non-grandfathered plans): independent external review by an accredited IRO if the internal appeal is denied.
- You generally have approximately four months from the denial date to request external review.
- Expedited review: available when your physician documents that the standard timeline would jeopardize your health or ability to use time-sensitive reproductive options.
## Concrete Appeal Timeline
1. Obtain the denial letter identifying the specific prior test Cigna considers duplicative. 2. Have your ordering provider (reproductive endocrinologist, genetic counselor, or oncologist) prepare a letter distinguishing the clinical purposes of each test. 3. File the internal appeal with supporting records. 4. If denied, escalate to external review without delay.
## Documentation to Gather
- Prior test records: results of any previously performed genetic test, with the clinical indication noted at the time.
- Current test clinical indication: a written statement from the ordering provider describing the specific clinical question the new test is intended to answer and why it is not answered by prior results.
- Clinical context documentation: fertility treatment records, oncology records (if applicable), genetic counseling notes, and reproductive history.
- Genetic counselor's letter: genetic counselors are well-positioned to articulate why panels testing different variants or addressing different clinical questions are not duplicative.
- Timeline of testing and clinical decision points: showing how clinical circumstances changed between the prior test and the current request.
## Criteria-Mapping Structure
Obtain Cigna's current coverage policy for germline genetic testing in the reproductive/fertility context and map each requirement:
| Cigna Duplicate-Test Criterion | Your Rebuttal Evidence | |---|---| | Prior test identified as duplicate | [Identify prior test; explain clinical purpose distinction in letter] | | Clinical question not already answered | [Ordering provider's explanation of distinct indication] | | Time-sensitivity of reproductive context | [Fertility treatment timeline documentation] |
Verify the exact coverage criteria in Cigna's current published coverage policy for germline genetic testing and for fertility-related genetic services. Also confirm all clinical standards and recommended testing panels against authoritative professional society guidelines from organizations such as the American Society for Reproductive Medicine (ASRM), the American College of Medical Genetics (ACMG), or the American College of Obstetricians and Gynecologists (ACOG), as applicable to your situation.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →